Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ:AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its…
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
Aprea Therapeutics Inc (NASDAQ:APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the…
Applied UV Announces Laboratory Results Confirming SteriLumen’s Lumicide Ribbon Kills SARS-CoV-2
Previously reported independent lab results confirmed killing OC43 human coronavirus ("OC43"), a common surrogate for SARS-CoV-2, the virus that causes COVID-19
MOUNT VERNON, NY / ACCESSWIRE / June 16, 2021
Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial
The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ:PSTV) to proceed to the eighth cohort of Phase 1…
MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
MacroGenics Inc (NASDAQ:MGNX) and Zai Lab Limited (NASDAQ:ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.…
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Lumen Bioscience And Novo Nordisk Enter Research Collaboration To Explore Novel Strategies To Deliver Oral Biologics For Cardiometabolic Disease; Financial Details Not Disclosed
https://www.prnewswire.com/news-releases/lumen-bioscience-and-novo-nordisk-enter-into-research-collaboration-to-explore-novel-strategies-to-deliver-oral-biologics-for-cardiometabolic-disease-301313338.html
Novocure Initiates Usability Study For Flexible Torso Array
New array intended to increase ease-of-use for torso and abdominal applications
Novocure (NASDAQ:NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will
MacroGenics And Zai Lab Enter Collaboration To Develop And Commercialize Preclinical Bispecific Antibodies in Oncology; MacroGenics To Receive Initial Consideration Of $55M, An Equity Investment And Is Eligible For $1.4B In Milestones
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules
MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms
KemPharm Issues Letter To Shareholders
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO